RE-ARMing the Immune Response to Bladder Cancer with Radiotherapy

Clin Oncol (R Coll Radiol). 2022 Jul;34(7):421-425. doi: 10.1016/j.clon.2021.12.019. Epub 2022 Jan 5.

Authors

A Wilkins¹, E Hall², R Lewis², H Gribble², A Melcher³, R Huddart³; RE-ARM Trial Management Group

Affiliations

¹ Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK; Royal Marsden Hospital, London, UK. Electronic address: Anna.wilkins@icr.ac.uk.
² Division of Clinical Studies, The Institute of Cancer Research, London, UK.
³ Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK; Royal Marsden Hospital, London, UK.

PMID: 34998656
DOI: 10.1016/j.clon.2021.12.019

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Immunity
Radiation Oncology*
Urinary Bladder Neoplasms* / radiotherapy

Grants and funding